The primary objectives of the study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Safety assessments include measurement of blood pressure, heart rate, serum potassium and kidney function as calculated by glomerular filtration rate (GFR). Clinical assessments include urine flow rate, sodium excretion rate and plasma cGMP, a secondary messenger of the target receptor. The trial is expected to enroll up to approximately 35 patients.
Peter Strumph, CEO of Nile, said: “This trial provides us our first opportunity to assess the drug’s activity in heart failure patients, and to further build on our understanding of the molecule’s mechanism of action.”